English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/125938
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations

AuthorsMatos, Liliana; Desviat, Lourdes R. ; Pérez, Belén ; Vilageliu, Lluïsa
KeywordsSplicing mutations
Modified U1 snRNAs
Sanfilippo C syndrome
Lysosomal storage disorder
Glucosamine
Issue Date10-Dec-2014
PublisherBioMed Central
CitationOrphanet Journal of Rare Diseases 9(1):180 (2014)
Abstract[Background] Mutations affecting RNA splicing represent more than 20% of the mutant alleles in Sanfilippo syndrome type C, a rare lysosomal storage disorder that causes severe neurodegeneration. Many of these mutations are localized in the conserved donor or acceptor splice sites, while few are found in the nearby nucleotides.
[Methods] In this study we tested several therapeutic approaches specifically designed for different splicing mutations depending on how the mutations affect mRNA processing. For three mutations that affect the donor site (c.234 + 1G > A, c.633 + 1G > A and c.1542 + 4dupA), different modified U1 snRNAs recognizing the mutated donor sites, have been developed in an attempt to rescue the normal splicing process. For another mutation that affects an acceptor splice site (c.372-2A > G) and gives rise to a protein lacking four amino acids, a competitive inhibitor of the HGSNAT protein, glucosamine, was tested as a pharmacological chaperone to correct the aberrant folding and to restore the normal trafficking of the protein to the lysosome.
[Results] Partial correction of c.234 + 1G > A mutation was achieved with a modified U1 snRNA that completely matches the splice donor site suggesting that these molecules may have a therapeutic potential for some splicing mutations. Furthermore, the importance of the splice site sequence context is highlighted as a key factor in the success of this type of therapy. Additionally, glucosamine treatment resulted in an increase in the enzymatic activity, indicating a partial recovery of the correct folding.
[Conclusions] We have assayed two therapeutic strategies for different splicing mutations with promising results for the future applications.
DescriptionMatos, Liliana et al.
Publisher version (URL)http://dx.doi.org/10.1186/s13023-014-0180-y
URIhttp://hdl.handle.net/10261/125938
DOI10.1186/s13023-014-0180-y
ISSN1750-1172
Appears in Collections:(CBM) Artículos
Files in This Item:
File Description SizeFormat 
13023_2014_Article_180.pdf1,38 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.